Autodesk CMO Dara Treseder discusses how she is leading the software giant through the AI shift with a new brand campaign, "The World is Yours for the Making," which emphasizes human creativity. She explains her approach to marketing, highlighting the emotional aspect of B2B purchases and the importance of supporting her global marketing team through technological advancements. Treseder also shares insights from her diverse CMO experience at Peloton, GE, and Carbon, emphasizing curiosity, conviction, and courage.

Moderna (MRNA) stock surged 8% despite its biotech peers BioNTech and Merck remaining largely flat, suggesting a stock-specific event rather than a sector-wide trend. The rally comes after Moderna had already seen a 143% increase in the past month due to a successful late-stage melanoma trial in August, with no new clinical or regulatory triggers for Friday's jump. Analysts suggest the movement is likely due to momentum buying or a short squeeze, given the absence of new fundamental news.

Moderna (NASDAQ: MRNA) stock surged 8% despite no specific news, trial readouts, or analyst calls, while its peers BioNTech and Merck remained flat or slightly down. This unexpected rally follows a 143% gain over the past month due to a successful late-stage melanoma trial in August. The current surge is likely driven by momentum buying or a short squeeze, as broader market and sector movements do not account for Moderna's stock-specific event.

Apple Inc. (AAPL) saw its shares jump 3.6% after unveiling its new $1,999 foldable iPhone Duo. In contrast, Lennar Corporation (LEN) shares fell 3.5% due to rising mortgage rates, and Newmont Corporation (NEM) declined 2% as the materials sector suffered. AT&T Inc. (T) shares rose 1.6%, despite its CEO questioning Apple's foldable phone technology.

JPMorgan Chase & Co. (JPM) currently has an average brokerage recommendation (ABR) of 2.00, indicating a "Buy" based on recommendations from 26 brokerage firms. However, the article cautions against relying solely on ABRs due to potential analyst bias, suggesting that the Zacks Rank, which incorporates earnings estimate revisions, provides a more reliable indicator for near-term stock performance. JPM currently holds a Zacks Rank #2 (Buy) due to growing optimism in its earnings prospects.

Bank of Montreal (BMO) has pledged up to $70 billion in new capital over the next decade to support critical sectors of Canada's economy, including electricity, energy, transportation, mining, AI, and defence. This initiative aligns with the Canadian government's push to strengthen economic security and reduce reliance on the United States. Other Canadian banks, such as RBC, CIBC, Scotiabank, and National Bank, are also making similar commitments to bolster key industries.

Bonk, Inc. (NASDAQ:BNKK) has redeemed 26.7% of its Series A Preferred Stock from Core4 Capital Holdings Corp for $4 million, reducing Core4’s holdings and eliminating anti-dilution rights. CEO Jarrett Boon stated this action defends shareholder value, cleans up the capital structure, and provides a clear path for future growth. The redeemed shares have been retired and restored to unissued status.

Cintas (CTAS) is outperforming other Consumer Discretionary stocks this year, with a year-to-date return of 5.5% compared to the sector's average loss of 12.3%. The company holds a Zacks Rank #2 (Buy), driven by improving analyst sentiment and a positive earnings outlook. PIGEON CORP (PGENY) is another Consumer Discretionary stock showing strong performance, up 15.2% year-to-date, also with a Zacks Rank #2 (Buy).

Apimeds Pharmaceuticals US has announced a restructuring of its board of directors and the appointment of Sungjoon Chae as a new director. This change follows an amendment to a previous settlement agreement involving the company and its subsidiaries. Sungjoon Chae, who also serves as Co-Chief Executive Officer, joins the board after being nominated by the Inscobee Parties.

Barclays PLC has reduced its holding in Central Asia Metals PLC to 5.62% from 5.66%, crossing a key threshold on September 9. The banking group's total position now comprises 3.52% voting rights attached to shares and 2.10% through financial instruments. Barclays Capital Securities Limited holds the direct voting rights, with additional voting rights held via rights to recall, contracts for difference, and portfolio swaps.